$4.16
+0.71 (+20.58%)
Open$3.61
Previous Close$3.45
Day High$4.31
Day Low$3.45
52W High$4.31
52W Low$1.19
Volume—
Avg Volume2.00M
Market Cap264.42M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Hold
13 analysts
Price Target
+954.1% upside
Current
$4.16
$4.16
Target
$43.85
$43.85
$27.62
$43.85 avg
$64.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 150.47M | 151.27M | 19.43M |
| Net Income | -75,099,826 | -67,949,978 | 4.04M |
| Profit Margin | -49.9% | -47.4% | 20.8% |
| EBITDA | -63,416,924 | -60,567,083 | 6.14M |
| Free Cash Flow | — | — | 2.37M |
| Rev Growth | -0.5% | -0.5% | +14.5% |
| Debt/Equity | 1.26 | 1.26 | 0.18 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |